No Data
Institutional Investors Control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Were Rewarded Last Week After Stock Increased 4.9%
BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Express News | BioCryst Pharmaceuticals Inc - Seeks to Block FDA Approval of Generic Orladeyo Until Patent Expiration
Executive Reshuffles: SBUX, KR, and LVS